Download MendeleyStructure-based design and discovery of potent and selective KDM5 inhibitors.
Nie, Z., Shi, L., Lai, C., O'Connell, S.M., Xu, J., Stansfield, R.K., Hosfield, D.J., Veal, J.M., Stafford, J.A.(2018) Bioorg Med Chem Lett 28: 1490-1494
- PubMed: 29627262
- DOI: https://doi.org/10.1016/j.bmcl.2018.03.083
- Primary Citation of Related Structures:
6CG1, 6CG2 - PubMed Abstract:
Histone lysine demethylases (KDMs) play a key role in epigenetic regulation and KDM5A and KDM5B have been identified as potential anti-cancer drug targets. Using structural information from known KDM4 and KDM5 inhibitors, a potent series of pyrazolylpyridines was designed. Structure-activity relationship (SAR) exploration resulted in the identification of compound 33, an orally available, potent inhibitor of KDM5A/5B with promising selectivity. Potent cellular inhibition as measured by levels of tri-methylated H3K4 was demonstrated with compound 33 in the breast cancer cell line ZR-75-1.
Organizational Affiliation:
Celgene Corporation, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA. Electronic address: znie@celgene.com.
